197 related articles for article (PubMed ID: 12198665)
21. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
Borroto-Esoda K; Myrick F; Feng J; Jeffrey J; Furman P
Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
[TBL] [Abstract][Full Text] [Related]
22. Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation.
Yang L; Shi LP; Chen HJ; Tong XK; Wang GF; Zhang YM; Wang WL; Feng CL; He PL; Zhu FH; Hao YH; Wang BJ; Yang DL; Tang W; Nan FJ; Zuo JP
Acta Pharmacol Sin; 2014 Mar; 35(3):410-8. PubMed ID: 24487969
[TBL] [Abstract][Full Text] [Related]
23. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
Tomita T; Yokosuka O; Tagawa M; Saisho H; Tamura S; Fukuda I; Omata M
J Hepatol; 2000 May; 32(5):850-8. PubMed ID: 10845674
[TBL] [Abstract][Full Text] [Related]
24. [Experimental study on the effect of combination therapy with lamivudine and famciclovir against duck hepatitis B virus in vivo].
Chen Y; Guo S; Qi Z; Huang A
Zhonghua Gan Zang Bing Za Zhi; 2001 Aug; 9(4):209-11. PubMed ID: 11602049
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs.
Narayanasamy J; Pullagurla MR; Sharon A; Wang J; Schinazi RF; Chu CK
Antiviral Res; 2007 Sep; 75(3):198-209. PubMed ID: 17532483
[TBL] [Abstract][Full Text] [Related]
26. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine.
Severini A; Liu XY; Wilson JS; Tyrrell DL
Antimicrob Agents Chemother; 1995 Jul; 39(7):1430-5. PubMed ID: 7492080
[TBL] [Abstract][Full Text] [Related]
28. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Karatayli E; Karayalçin S; Karaaslan H; Kayhan H; Türkyilmaz AR; Sahin F; Yurdaydin C; Bozdayi AM
Antivir Ther; 2007; 12(5):761-8. PubMed ID: 17713159
[TBL] [Abstract][Full Text] [Related]
29. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
[TBL] [Abstract][Full Text] [Related]
30. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
[TBL] [Abstract][Full Text] [Related]
31. Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks.
Fourel I; Li J; Hantz O; Jacquet C; Fox JJ; Trépo C
J Med Virol; 1992 Jun; 37(2):122-6. PubMed ID: 1629711
[TBL] [Abstract][Full Text] [Related]
32. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
33. Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes.
Schorr O; Borel C; Trepo C; Zoulim F; Hantz O
J Hepatol; 2006 May; 44(5):842-7. PubMed ID: 16458387
[TBL] [Abstract][Full Text] [Related]
34. [Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B].
Chen XM; Liu ZM; Du XF; Yang ZG; Chen XM
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 34(2):121-5. PubMed ID: 15812884
[TBL] [Abstract][Full Text] [Related]
35. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
[TBL] [Abstract][Full Text] [Related]
36. Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.
Feng JY; Myrick F; Selmi B; Deval J; Canard B; Borroto-Esoda K
Antiviral Res; 2005 Jun; 66(2-3):153-8. PubMed ID: 15885814
[TBL] [Abstract][Full Text] [Related]
37. Antisense therapy of hepatitis B virus infection.
Offensperger WB; Offensperger S; Blum HE
Mol Biotechnol; 1998 Apr; 9(2):161-70. PubMed ID: 9658393
[TBL] [Abstract][Full Text] [Related]
38. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
39. Isolation and identification of an anti-hepatitis B virus compound from Hydrocotyle sibthorpioides Lam.
Huang Q; Zhang S; Huang R; Wei L; Chen Y; Lv S; Liang C; Tan S; Liang S; Zhuo L; Lin X
J Ethnopharmacol; 2013 Nov; 150(2):568-75. PubMed ID: 24051027
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Fu L; Liu SH; Cheng YC
Biochem Pharmacol; 1999 Jun; 57(12):1351-9. PubMed ID: 10353255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
